CCM
AMLX icon

CAAS Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

CAAS Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,000
Closed -$218K – 889
2022
Q1 		$218K Buy
+17,000
New +$384K 0.01% 450

Other funds holding AMLX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAAS Capital Management's AMLX Position: Q2 2022 in Review

CAAS Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2022, closing a stake of 17,000 shares — an estimated $218K sold.

CAAS Capital Management first reported a position in AMLX in Q1 2022 and held it in 1 quarter. The position peaked at $218K in Q1 2022. 78 funds tracked by Wall St. Rank hold AMLX as of Q2 2022.

  • CAAS Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • CAAS Capital Management sold 17,000 Amylyx Pharmaceuticals shares in Q2 2022, an estimated $218K.
  • CAAS Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • CAAS Capital Management's Amylyx Pharmaceuticals position peaked at $218K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2022.

Based on CAAS Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.